Olmesartan Medoxomil Accord Healthcare (Olmesartan Medoxomil)

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the angiotensin II receptor pathway.

• Hypertension: provides sustained reduction of systolic and diastolic blood pressure.
• Hypertension with type 2 diabetes: helps control blood pressure while offering renal protective benefits.
• Hypertension in elderly patients: delivers effective blood pressure control with a favorable tolerability profile.

• Olmesartan medoxil selectively blocks the binding of angiotensin II to the AT1 receptor on vascular smooth muscle and adrenal gland cells. This inhibition prevents vasoconstriction and aldosterone secretion, leading to vasodilation, reduced sodium and water retention, and ultimately a decrease in systemic blood pressure.

Adverse reactions may occur with olmesartan therapy and are categorized by frequency.

Common Side Effects

• Dizziness: light‑headed sensation, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: general feeling of tiredness.
• Abdominal pain: discomfort in the stomach area.
• Back pain: musculoskeletal discomfort.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat.
• Hyperkalemia: elevated potassium levels in blood.
• Acute renal failure: sudden loss of kidney function.
• Severe hypotension: marked drop in blood pressure.
• Hepatic injury: abnormal liver enzyme elevations.

Before initiating therapy, consider the following safety measures.

• Blood pressure monitoring: ensure target levels are achieved without excessive drop.
• Renal function assessment: evaluate serum creatinine and eGFR periodically.
• Serum potassium check: monitor for hyperkalemia, especially with concomitant potassium‑sparing agents.
• Pregnancy avoidance: do not use in pregnant women due to fetal toxicity risk.
• Hepatic impairment caution: adjust use in patients with significant liver disease.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): combined use can increase renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics (e.g., spironolactone): risk of dangerous hyperkalemia.
• ACE inhibitors (concurrent use): heightened risk of angioedema and renal impairment.
• NSAIDs (high‑dose or chronic): may diminish antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: additive blood‑pressure lowering effect, monitor for hypotension.
• Lithium: olmesartan can raise lithium concentrations, requiring serum level checks.
• Cyclosporine: may increase risk of nephrotoxicity, monitor renal parameters.
• Rifampin: can reduce olmesartan plasma levels, consider alternative therapy.